Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues

v3.23.1
Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]      
Total revenues 100.00% 100.00% 100.00%
Cipher Pharmaceuticals [Member]      
Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]      
Total revenues 11.00% 12.00% 20.00%
Chong Kun Dang Pharmaceuticals Corp [Member]      
Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]      
Total revenues 25.00% 24.00% 45.00%
Gebro Holding GmBH [Member]      
Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]      
Total revenues 18.00% 23.00% 35.00%
Ewopharma AG [Member]      
Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]      
Total revenues 46.00% 41.00%